Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BY 4.0The Lancet. Microbe

WHO Target Product Profiles for Dengue Therapeutics: An Interdisciplinary Analysis of Ethical, Regulatory, and Implementation Considerations

  • Tess Johnson1,2
  • Shanghavie Loganathan3
  • Euzebiusz Jamrozik1,4
  • Michael J Parker1,2
  • Xin Hui S Chan5,6
6 affiliations
  1. 1Ethox Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  2. 2Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, United Kingdom
  3. 3Department of Paediatrics, Homerton Healthcare NHS Foundation Trust, London, United Kingdom
  4. 4Department of Infectious Diseases, University of Melbourne, Melbourne, Australia
  5. 5Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  6. 6Epidemic and Emerging Infections Directorate, United Kingdom Health Security Agency, London, United Kingdom
Read full textPDFDOICite

Abstract

Dengue, a mosquito-borne viral disease, is experiencing its largest surge in history, driven by climate and demographic change. Expanding transmission has highlighted previously under-recognised populations at heightened risk of severe disease, including people with multimorbidity and immunosuppression, for whom live-attenuated vaccines are contraindicated or unlicensed. This evolving epidemiology underscores the urgent need for safe and effective treatments for dengue, particularly for those with complex risk profiles compounded by socio-economic disadvantage. We examine ethical, regulatory, and implementation considerations to support World Health Organization target product profile development for dengue therapeutics. Our analysis highlights the need for better characterisation of risk groups, including through enhanced surveillance; co-produced approaches for their inclusion in research prioritisation, trials, and care; and strategies to address key barriers to access for all, such as rapid diagnostics. This framework has the potential to inform equitable development and delivery of countermeasures for other infectious threats to global health.

Related

  1. Seasonal Hip Strength Monitoring in Division I Women’s Ice Hockey with Strength Ratios and Implementation Considerations
    International journal of sports physical therapyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Focused ethnography protocol for exploring burn pain management practices in clinical settings: methodological considerations and implementation framework.
    Hanieh Aziz Karkan, Zahra Sheikhalipour, Asghar Izadi-Jeiran +2
    BMJ openPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCCrossref
  3. Implementation of an Interdisciplinary Clinical Pathway to Treat Chemotherapy-Induced Peripheral Neuropathy
    Kelly Preti, Rita D'aoust, Deborah Baker +2
    Journal of the Advanced Practitioner in OncologyPeer-reviewedCC BY-NC-ND 3.0Full textOncologyPMC
  4. Building a cardiovascular disease observatory in primary care in Crete, Greece: design, implementation, and lessons learned for interdisciplinary digital surveillance
    Marilena Anastasaki, Foteini Anastasiou, Fragiskos Parthenakis +1
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Cardiovascular medicineCrossref
  5. Immunomodulatory strategies for ex vivo immune cell expansion in adoptive cell therapy: translational and regulatory considerations for clinical manufacturing
    Weng Wan Chan, Estella Zhi Yu Lim, Deepak Choudhury
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{johnson2026target,
  title = {{WHO Target Product Profiles for Dengue Therapeutics: An Interdisciplinary Analysis of Ethical, Regulatory, and Implementation Considerations}},
  author = {Tess Johnson and Shanghavie Loganathan and Euzebiusz Jamrozik and Michael J Parker and Xin Hui S Chan},
  journal = {The Lancet. Microbe},
  year = {2026},
  month = nov,
  doi = {10.1016/j.lanmic.2026.101466},
  url = {https://doi.org/10.1016/j.lanmic.2026.101466},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - WHO Target Product Profiles for Dengue Therapeutics: An Interdisciplinary Analysis of Ethical, Regulatory, and Implementation Considerations
AU  - Tess Johnson
AU  - Shanghavie Loganathan
AU  - Euzebiusz Jamrozik
AU  - Michael J Parker
AU  - Xin Hui S Chan
PY  - 2026
DA  - 2026/11/04
JO  - The Lancet. Microbe
DO  - 10.1016/j.lanmic.2026.101466
UR  - https://doi.org/10.1016/j.lanmic.2026.101466
AB  - Dengue, a mosquito-borne viral disease, is experiencing its largest surge in history, driven by climate and demographic change. Expanding transmission has highlighted previously under-recognised populations at heightened risk of severe disease, including people with multimorbidity and immunosuppression, for whom live-attenuated vaccines are contraindicated or unlicensed. This evolving epidemiology underscores the urgent need for safe and effective treatments for dengue, particularly for those with complex risk profiles compounded by socio-economic disadvantage. We examine ethical, regulatory, and implementation considerations to support World Health Organization target product profile development for dengue therapeutics. Our analysis highlights the need for better characterisation of risk groups, including through enhanced surveillance; co-produced approaches for their inclusion in research prioritisation, trials, and care; and strategies to address key barriers to access for all, such as rapid diagnostics. This framework has the potential to inform equitable development and delivery of countermeasures for other infectious threats to global health.
SN  - 2666-5247
ER  -